Article

Blepharoptosis in patients with an ocular prosthesis: Use of a novel template prosthesis

Author(s):

Learn about a novel procedure using a template prosthesis to facilitate intraoperative adjustment during external levator resection ptosis repair.

Blepharoptosis in patients with an ocular prosthesis: Use of a novel template prosthesis

Study authors found that using a template prosthesis to facilitate intraoperative lid positioning in ptosis repair was effective in 12 patients.

Changyow Kwan, MD, and colleagues from the Division of Oculofacial Plastic and Orbital Surgery, Gavin Herbert Eye Institute, Department of Ophthalmology, University of California-Irvine, Irvine, CA, determined the effectiveness of use of a template prosthesis to facilitate intraoperative lid positioning in ptosis repair. All patients had a good esthetic result and no complications developed.

Blepharoptosis develops frequently in patients with acquired anophthalmia, but according to Kwan, the optimal treatments have not been ascertained.

The authors undertook a literature search to identify reports of pathophysiology or management of blepharoptosis in this patient population and they describe the results of procedure using a template prosthesis to facilitate intraoperative adjustment during external levator resection ptosis repair.

They ultimately identified 13 articles in the literature that met the inclusion criteria that included description of the pathophysiology/treatment of anophthalmic blepharoptosis. The authors also reviewed the cases of 12 adults who underwent external levator resection using a limbal templated, non-detailed, custom-shaped prosthesis.

The investigators assessed the results, specifically the margin to reflex distance 1 (MRD1), facial symmetry, and the number of eye prosthesis modifications.

Kwan and colleagues commented that, based on the literature, levator pathophysiology and orbital volume loss are important variables in anophthalmic ptosis.

“Prosthesis augmentation may be useful to treat ptosis in many instances, but may be limited by decreased motility and a poorer overall prosthesis fit. A number of surgical techniques of blepharoptosis repair have been reported and the success rates ranged from 88% to 100%,” they said.

They found that using a template prosthesis to facilitate intraoperative lid positioning in ptosis repair was effective in 12 patients. All patients had MRD1 within 1 mm of the target and all had good facial symmetry. No complications developed and revisions of the ptosis repair or redundancy in prosthesis fabrication were not needed after a mean of 3 years of follow-up, they reported.

Reference
  1. Kwan CC, Dermarkaria, CR, Cypen SG, et al. Blepharoptosis in the setting of an ocular prosthesis: a literature review and description of the novel use of a template prosthesis. touchREVIEWS in Ophthalmology. 2022;16(1): published online May 9, 2022.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
© 2025 MJH Life Sciences

All rights reserved.